Schwarzschild MA, Ascherio A, Casaceli C, et al. - According to this randomized clinical trial, treatment with inosine, compared with placebo, did not result in a meaningful change in the rate of clinical disease progression among individuals newly diagnosed with Parkinson disease (PD). The results do not support the use of inosine as a therapy for early PD.

• The research was terminated early based on a prespecified interim futility analysis, with 273 (92%) of the randomized participants (49% women; mean age, 63 years) completing the study.

• Clinical progression rates did not differ significantly between those assigned to inosine or placebo.

• The inosine group experienced a sustained increase in serum urate of 2.03 mg/dL compared with a 0.01-mg/dL rise in the placebo group.

• There were no statistically significant differences in secondary efficacy results, such as dopamine transporter binding loss.

• Inosine participants had fewer major adverse events but more kidney stones than placebo participants.